HSTI
High Sierra Technologies, Inc.1.4000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
29.12MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q3 FY2023 results
High Sierra Technologies posted zero revenues for Q3 ended September 30, 2023, with operating loss widening to $73K (up 110% y/y) on higher professional services to $41K and contract services to $17K, while net loss hit $94K versus $52K last year due to added debt discount amortization. Nine-month operating loss reached $225K (up 35% y/y), net loss $285K, with EPS at -$0.01 matching diluted shares of 20.6M. Cash edged to $17K on $124K financing inflows including $104K convertible notes, yet total debt climbed to $611K (12-16% rates, maturities 2023-2026) against $823K liabilities. Organipure JV began hemp smokables production using licensed patents, eyeing Q4 revenue. Debt fuels the burn.
10-Q
Q2 FY2023 results
High Sierra Technologies posted zero revenues for Q2 ended June 30, 2023, with operating loss widening to $77,117 (up 123% y/y) on higher general and administrative expenses of $67,980, while net loss hit $96,004 after $18,887 other expenses from interest and debt discount amortization. Cash drained to $1,878 from operating use of $46,380 YTD, offset by $36,000 financing including $25,000 stock sales; total debt stood at $482,671 mostly current at 12-16% rates due through 2024. Organipure JV with Hempacco licenses patents for hemp smokables through 2033 at 5% of gross receipts. Cash stays razor-thin. Competition shadows hemp smokables.
10-Q
Q1 FY2023 results
High Sierra Technologies posted no revenue for Q1 ended March 31, 2023, but narrowed its operating loss to $75,219 (down 23% y/y from $97,930) and net loss to $95,144 (down 17% y/y from $114,054), thanks to lower general and administrative expenses at $64,082 while depreciation ticked up to $11,137. The net loss exceeded operating loss due to $19,925 in other expenses, mainly interest and debt discount amortization. Cash dwindled to $8,543 amid $14,715 operating burn, offset by $10,000 notes payable inflow; total debt hit $683K against $82K assets, with substantial doubt on going concern flagged. Organipure JV licenses patents to Hempacco at 5% of gross receipts through 2033. Cash stays tight.
10-K
FY2022 results
High Sierra Technologies posted zero revenue for FY2022 ended December 31, 2022, with operating loss of $238,364 on $181,971 G&A and $56,393 depreciation—down from $255,926 operating loss in 2021—while net loss widened slightly to $323,952 ($0.01/share) from $316,437 ($0.02/share), driven by $17,518 debt discount amortization atop $66,473 interest. Cash dwindled to $12,258 from $55,351, with $220,000 financing inflows matching $219,659 operating burn; $43,435 capex hit property, plant to $77,386 net. No Q4 breakdowns disclosed. November joint venture with Hempacco launched first patent licensing via 50%-owned Organipure, but going concern doubts loom. Liquidity strains from $612K liabilities persist.
8-K
Auditor switch disclosed
High Sierra Technologies dismissed Pinnacle Accountancy Group as its auditor on December 29, 2022, effective immediately, after clean reports save for going-concern doubts; no disagreements occurred. It appointed TAAD, LLP on February 1, 2023. No prior consultations. Clean switch, but viability lingers.
IPO
Website
Sector
Industry
CBIH
CANNABIS BIOSCIENCE INTERNATION
0.00-0.00
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.10+0.03
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
GSTK
Growth Stalk Holdings Corp
3.00+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
JUSHF
Jushi Holdings Inc.
0.84+0.11
MAJI
Marijuana Inc.
0.05-0.02
MSTH
Mystic Holdings Inc.
0.01+0.00
NTRR
Neutra Corp.
0.00+0.00
NXEN
Nexien BioPharma, Inc.
0.00+0.00